Purple Biotech (PPBT) Other Accumulated Expenses (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Other Accumulated Expenses data on file, last reported at $1.7 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $1.7 million, up 24.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 24.37% YoY), and the FY2025 annual result was $1.4 million, up 14.42% from the prior year.
• Other Accumulated Expenses grew to $1.7 million in Q1 2026 per PPBT's latest filing, from $1.4 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $5.3 million in Q1 2022 and troughed at $1.2 million in Q2 2025.
• A 5-year average of $2.6 million and a median of $2.8 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses jumped 223.72% in 2022, then tumbled 65.35% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $4.7 million in 2022, then decreased by 26.82% to $3.5 million in 2023, then plunged by 65.35% to $1.2 million in 2024, then increased by 14.42% to $1.4 million in 2025, then advanced by 21.56% to $1.7 million in 2026.
• Business Quant data shows PPBT's Other Accumulated Expenses at $1.7 million in Q1 2026, $1.4 million in Q4 2025, and $1.2 million in Q3 2025.